Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Disease area: Airway diseases

Abstract

Introduction: Omalizumab is recommended in the treatment of patients with refractory asthma; response to this expensive therapy is not uniform. The characteristics associated with good treatment response are poorly defined.
Objectives: Our goal was to determine what patient characteristics, other than atopy and IgE level, might predict response to therapy with omalizumab.
Methods: We carried out a retrospective review of adult patients, followed at a tertiary asthma clinic, who received treatment with omalizumab for at least 6 months. The following data were collected: IgE level, atopy, sputum eosinophils and neutrophils, blood eosinophils, associated rhinosinusitis / nasal polyps. Response to therapy was judged by one asthma specialist and an asthma nurse clinician based on maintenance therapy required, exacerbations, FEV1 and ACQ score. Groups were compared using Chi-square and t-tests.
Results: 17 patients were included; 12 were considered to have responded to omalizumab. Of 13 patients who provided induced sputum for inflammatory profile, 9 were classified as responders. All responders had elevated sputum eosinophils (> 2%) vs 25% of non-responders (p=0.014) but none had high neutrophils (>65%) vs all non-responders (p= 0.001). Elevated blood eosinophilia (> 0.5 x10^9/L) was present in 82% of responders while 80% of non-reponders had results within normal limits (p= 0.036).
Conclusions: Sputum inflammatory profile and blood eosinophils predict response to omalizumab among atopic patients with refractory asthma.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Rioux, C. Robitaille, P. Ernst (Montreal, Canada). Characteristics of asthma patients responding to anti-IgE therapy. Eur Respir J 2013; 42: Suppl. 57, 4163

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Adherence to the treatment of patients with bronchial asthma Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 The parameters that may affect inhalation therapy success in elderly COPD and asthma patients Source: International Congress 2015 – Co-existing diseases and asthma Year: 2015 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Finding asthmatics suitable for omalizumab therapy in a district hospital Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Knowledge of asthma is associated with inhalation technique in elderly patients with asthma Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Determinants of non-adherence to pharmacologic allergic rhinitis treatment Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Efficacy of carbamazepine in treatment of bronchial asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 The remarkable role of adherence to inhaled corticosteroids in achieving asthma control in young children with asthma Source: Annual Congress 2013 –Preschool wheeze Year: 2013